Search
forResearch 10 of 985
- A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors.
- Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children
- XMU-MP-1 induces growth arrest in a model human mini-organ and antagonises cell cycle-dependent paclitaxel cytotoxicity
- Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- New drugs under investigation for the treatment of alopecias
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Integrated single-cell chromatin and transcriptomic analyses of peripheral immune cells in patients with alopecia areata
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Mechanisms of autophagy and their implications in dermatological disorders
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →